Adagene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Adagene sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Adagene: 6 sponsored US clinical trials, 1 recruiting.
Adagene sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced/Metastatic Solid Tumors, with 1 trials.
Upper-quartile sponsor footprint
Adagene sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05277402
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
NCT04645069
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
NCT04501276
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
NCT04111445
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
NCT03707093
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Therapeutic Areas
What is open in the Adagene pipeline
1 recruiting of 6 indexed (17% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Advanced/Metastatic Solid Tumors (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Adagene: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Adagene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Adagene page
6 registered trials is a research-attention snapshot, not an endorsement of Adagene or any single study.
- 1 of Adagene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced/Metastatic Solid Tumors is the condition Adagene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced/Metastatic Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Adagene pipeline card: 6 registered trials from official public datasets.Report a data error.